Phase 4 N=90 Tobacco Use Treatment in Cancer Patients
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=359 Novel Determinants and Measures of Smokeless Tobacco Use: Study 1
Smokeless Tobacco Use · Tobacco Dependence
Primary: Extent of Toxicity: Mean of Median Values of NNK+NNN in 7 Smokeless Tobacco Brands — 2.4; 2.25; 3.19; 5.51 ug/g
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
Phase 3 N=81 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Tobacco Dependence
Primary: Tobacco Abstinence at 12 Weeks — 8; 5 participants
N/A N=51 Health-Kit Enabled Mobile App for Tobacco Cessation
Cigarette Smoking
Primary: Psychosocial Expectancies (PROMIS Smoking Initiative) Patient Reported Outcome — 12.7; 13.6 score on a scale — p=0.17
Phase 2 N=49 Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco
Nicotine Dependence, Cigarettes, Uncomplicated
Primary: Average Cigarettes Smoked Per Day — 4.3; 8.0 average cigarettes per day — p=.111
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
N/A N=5,123 Proactive Tobacco Treatment for Veterans
Smoking Cessation · Smoking Tobacco
Primary: Self-reported, Smoking Abstinence Rate: 6-month Prolonged Abstinence — 10.9; 13.5 percentage of participants — p=.02
N/A N=104 Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Tobacco Use Disorder
Primary: Product Preference — 27; 23; 24; 24 participants
N/A N=67 Clinical Trial Tobacco Marijuana
Cannabis Use Disorder · Tobacco Use Disorder
Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33
Phase 4 N=181 Cannabis and Tobacco Co-use Study
Tobacco Use Disorder
Primary: Number of Participants With Biologically Verified 7-day Point Prevalence Tobacco Abstinence at the End of Treatment (Week 12) — 30; 40; 36; 42 Participants
N/A N=187 Effects Among Smokers Who Use and Do Not Use E-Cigarettes
Toxicant Exposure
Primary: Toxicant Exposure — 40; 97 pg/ml
Phase 4 N=179 Smoking Tobacco and Drinking Study
Smoking · Heavy Episodic Drinking
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at 3 Months — 3; 4 Participants
Phase 2 N=130 Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
N/A N=234 Changes in Biomarkers Associated With Use of Electronic Cigarettes
Biomarkers
Primary: Change in Biomarker Concentrations: Nicotine Equivalents — 74.9; 79.56 mmol/mg creatinine
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
N/A N=685 Improving Tobacco Treatment Rates for Cancer Patients Who Smoke
Cancer · Tobacco Use · Smoking
Primary: Intervention Ordering Rate — 113; 60 Participants
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 2 N=332 Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use
Tobacco Use Disorder
Primary: Percent Abstinent From Tobacco at Week 12 (7 Day Point Prevalence) — 31; 17 percentage of randomized — p=0.04
N/A N=832 Testing an Organizational Change Model to Address Smoking in Mental Healthcare
Nicotine Dependence
Primary: Client Reported Tobacco Medications — 48; 28; 62; 24 Participants
Phase 4 N=30 Tobacco Cessation Treatment Preferences Among Veteran Smokers
Tobacco Use
Primary: Number of Participants Who Report Post-treatment Satisfaction — 15; 10 Participants
Phase 2 N=237 Efficacy of Varenicline for Smokeless Tobacco Use in India
Tobacco Use Disorder
Primary: 7-day Point Prevalence Smokeless Tobacco Abstinence Biochemically Confirmed With Urine Cotinine at the End of 12 Weeks of Treatment. — 30; 23 participants
N/A N=1,132 Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes
Tobacco Use, Cigarette Use
Primary: Very Low Nicotine Content (VLNC) Misperception — 3.12; 3.04; 3.04; 3.36 score on a scale
N/A N=105 Young Adult EC Use and Respiratory Outcomes
E Cig Use
Primary: Spirometry to Measure the Change From Baseline in Forced Vital Capacity (FVC) — 4.42; 3.54; 4.61; 3.68 liter
N/A N=60 Comparison of the Substitution Between Different Tobacco/Nicotine Products as a Function of Tobacco-user Type
Cigarette Smoking · Nicotine Vaping
Primary: Nicotine/Tobacco Products Substitution — 12.11; 4.82; 25.28; 17.08 mg of nicotine purchased — p=0.9793
N/A N=41 Tobacco Treatment in the Context of Lung Cancer Screening
Smoking Cessation
Primary: End of Treatment Abstinence Rates — 3; 0 Participants
Phase 2 N=94 Proactive Outreach for Smoking Treatment
Smoking, Tobacco · Mental Illness
Primary: Study 3: Smoking Abstinence — 3 Participants
N/A N=150 Methods Project 4: Clinical Trial
Smoker
Primary: Smoke-free Days — 14.5; 0; 0 days
N/A N=2,057 The Tobacco, Alcohol, Prescription Medication and Other Substances Tool
Substance Use Disorder
Primary: Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview…